Bridgewater Associates LP Has $12.59 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Bridgewater Associates LP grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 11.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 112,999 shares of the specialty pharmaceutical company’s stock after purchasing an additional 11,864 shares during the quarter. Bridgewater Associates LP owned about 0.19% of Jazz Pharmaceuticals worth $12,589,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc increased its holdings in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Jazz Pharmaceuticals in the second quarter valued at $29,000. EverSource Wealth Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC lifted its stake in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $33,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on JAZZ shares. Needham & Company LLC reissued a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. TD Cowen lowered their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Piper Sandler reissued an “overweight” rating and set a $163.00 price target (down from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. Royal Bank of Canada upped their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, October 23rd. Finally, Wells Fargo & Company dropped their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.33.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $122.64 on Friday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The firm has a market cap of $7.41 billion, a P/E ratio of 17.27, a P/E/G ratio of 1.05 and a beta of 0.57. The company’s 50-day moving average price is $114.66 and its two-hundred day moving average price is $111.07.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,110 shares of company stock valued at $720,160 in the last ninety days. 4.20% of the stock is currently owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.